Evidence from human studies suggests that parasitic worm infection can protect humans against rheumatoid arthritis (RA) and this idea is strengthened by data generated in model systems. Although therapeutic use of parasitic worms is currently being explored, there are obvious benefits in pursuing drug development through identification and isolation of the ‘active ingredients’. ES-62 is a secreted glycoprotein of the filarial nematode Acanthocheilonema viteae, which we have found to protect against the development of collagen-induced arthritis (CIA) in mice. ES-62 activity is dependent on the inflammatory phenotype of the local environment and protection arises via inhibition of Th17- and γδT cell-dependent IL-17 production. At the same time, NK and NK T cell IL-17 production is left intact, and such selectivity suggests that ES-62 might make a particularly attractive therapeutic for RA. However, as a potentially immunogenic protein, ES-62 is unsuitable for development as a drug. Nevertheless, ES-62 activity is dependent on covalently attached phosphorylcholine (PC) residues and we have therefore produced a library of PC-based drug-like ES-62 small-molecule analogues (SMAs) as an alternative therapeutic strategy. Screening this library, we have found an ES-62 SMA that mirrors ES-62 in protecting against CIA and by the same IL-17-dependent mechanism of action.
SubramanianSStolkWARamaiahKD. The dynamics of Wuchereria bancrofti infection: A model-based analysis of longitudinal data from Pondicherry, India. Parasitology2004; 128: 467–482.
2.
StrachanDP. Hay fever, hygiene, and household size. BMJ1989; 299: 1259–1260.
3.
GreenwoodBM. Autoimmune disease and parasitic infections in Nigerians. Lancet1968; 2: 380–382.
4.
GreenwoodBM. Polyarthritis in Western Nigeria. I. Rheumatoid arthritis. Ann Rheum Dis1969; 28: 488–496.
5.
PandaAKRavindranBDasBK. Rheumatoid arthritis patients are free of filarial infection in an area where filariasis is endemic: Comment on the article by Pineda et al. Arthritis Rheum2013; 65: 1402–1403.
6.
PearsonDJTaylorG. The influence of the nematode Syphacia oblevata on adjuvant arthritis in the rat. Immunology1975; 29: 391–396.
7.
HeYLiJZhuangW. The inhibitory effect against collagen-induced arthritis by Schistosoma japonicum infection is infection stage-dependent. BMC Immunol2010; 11: 28–28.
8.
ShiMWangAPrescottD. Infection with an intestinal helminth parasite reduces Freund’s complete adjuvant-induced monoarthritis in mice. Arthritis Rheum2011; 63: 434–444.
9.
SongXShenJWenH. Impact of Schistosoma japonicum infection on collagen-induced arthritis in DBA/1 mice: A murine model of human rheumatoid arthritis. PLoS One2010; 6: e23453–e23453.
10.
OsadaYShimizuSKumagaiTYamadaSKanazawaT. Schistosoma mansoni infection reduces severity of collagen-induced arthritis via down-regulation of pro-inflammatory mediators. Int J Parasitol2009; 39: 457–464.
11.
van den BiggelaarAHvan ReeRRodriguesLC. Decreased atopy in children infected with Schistosoma haematobium: A role for parasite-induced interleukin-10. Lancet2000; 356: 1723–1727.
12.
van RietEHartgersFCYazdanbakhshM. Chronic helminth infections induce immunomodulation: Consequences and mechanisms. Immunobiology2007; 212: 475–490.
13.
HarnettWHarnettMMByronO. Structural/functional aspects of ES-62 – a secreted immunomodulatory phosphorylcholine-containing filarial nematode glycoprotein. Curr Protein Pept Sci2003; 4: 59–71.
14.
GoodridgeHSWilsonEHHarnettWCampbellCCHarnettMMLiewFY. Modulation of macrophage cytokine production by ES-62, a secreted product of the filarial nematode Acanthocheilonema viteae. J Immunol2001; 167: 940–945.
15.
GoodridgeHSMarshallFAElseKJ. Immunomodulation via novel use of TLR4 by the filarial nematode phosphorylcholine-containing secreted product, ES-62. J Immunol2005; 174: 284–293.
16.
HarnettWGoodridgeHSAllenJMHarnettM. Receptor usage by the Acanthocheilonema viteae-derived immunomodulator, ES-62. Exp Parasitol2012; 132: 97–102.
17.
GoodridgeHSMcGuinessSHoustonKM. Phosphorylcholine mimics the effects of ES-62 on macrophages and dendritic cells. Parasite Immunol2007; 29: 127–137.
18.
PiccininiAMMidwoodKS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm2010; 2010.
19.
MelendezAJHarnettMMPushparajPN. Inhibition of Fc epsilon RI-mediated mast cell responses by ES-62, a product of parasitic filarial nematodes. Nat Med2007; 13: 1375–1381.
20.
BallDHTayHKBellKS. Mast cell subsets and their functional modulation by the Acanthocheilonema viteae product ES-62. J Parasitol Res2013; 2013: 961268–961268.
21.
DeehanMRHarnettMMHarnettW. A filarial nematode secreted product differentially modulates expression and activation of protein kinase C isoforms in B lymphocytes. J Immunol1997; 159: 6105–6111.
22.
DeehanMRFrameMJParkhouseRM. A phosphorylcholine-containing filarial nematode-secreted product disrupts B lymphocyte activation by targeting key proliferative signaling pathways. J Immunol1998; 160: 2692–2699.
PinedaMAMcGrathMASmithPC. The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17-producing cellular network at multiple sites. Arthritis Rheum2012; 64: 3168–3178.
25.
HarnettMMDeehanMRWilliamsDMHarnettW. Induction of signalling anergy via the T-cell receptor in cultured Jurkat T cells by pre-exposure to a filarial nematode secreted product. Parasite Immunol1998; 20: 551–563.
26.
HarnettWGoodridgeHSHarnettMM. Subversion of immune cell signal transduction pathways by the secreted filarial nematode product, ES-62. Parasitology2005; 130(Suppl): S63–S68.
27.
MarshallFAGriersonAMGarsidePHarnettWHarnettMM. ES-62, an immunomodulator secreted by filarial nematodes, suppresses clonal expansion and modifies effector function of heterologous antigen-specific T cells in vivo. J Immunol2005; 175: 5817–5826.
28.
GoodridgeHSHarnettWLiewFYHarnettMM. Differential regulation of interleukin-12 p40 and p35 induction via Erk mitogen-activated protein kinase-dependent and -independent mechanisms and the implications for bioactive IL-12 and IL-23 responses. Immunology2003; 109: 415–425.
29.
GoodridgeHSStepekGHarnettWHarnettMM. Signalling mechanisms underlying subversion of the immune response by the filarial nematode secreted product ES-62. Immunology2005; 115: 296–304.
30.
McInnesIBLeungBPHarnettMGracieJALiewFYHarnettW. A novel therapeutic approach targeting articular inflammation using the filarial nematode-derived phosphorylcholine-containing glycoprotein ES-62. J Immunol2003; 171: 2127–2133.
31.
SchurgersEBilliauAMatthysP. Collagen-induced arthritis as an animal model for rheumatoid arthritis: Focus on interferon-gamma. J Interferon Cytokine Res2011; 31: 917–926.
32.
Al-RiyamiLEganCABradleyJELustigmanSHarnettW. Failure of ES-62 to inhibit T-helper type 1 responses to other filarial nematode antigens. Parasite Immunol2008; 30: 304–308.
33.
Al-RiyamiLWilsonEHWatsonCAHarnettW. T-helper type 1 responses to the BCG vaccine component PPD in mice are unaffected by the filarial nematode immunomodulatory molecule ES-62. J Parasitol2009; 95: 1201–1204.
34.
KellnerH. Targeting interleukin-17 in patients with active rheumatoid arthritis: Rationale and clinical potential. Ther Adv Musculoskelet Dis2013; 5: 141–152.
35.
SuttonCEMielkeLAMillsKH. IL-17-producing gammadelta T cells and innate lymphoid cells. Eur J Immunol2012; 42: 2221–2231.
36.
van HamburgJPAsmawidjajaPSDavelaarN. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum2011; 63: 73–83.
37.
HuFLiYZhengL. Toll-like receptors expressed by synovial fibroblasts perpetuate Th1 and th17 cell responses in rheumatoid arthritis. PLoS One2014; 9: e100266–e100266.
38.
ParsonageGFilerABikM. Prolonged, granulocyte-macrophage colony-stimulating factor-dependent, neutrophil survival following rheumatoid synovial fibroblast activation by IL-17 and TNFalpha. Arthritis Res Ther2008; 10: R47–R47.
39.
GullickNJAbozaidHSJayarajDM. Enhanced and persistent levels of interleukin (IL)-17+CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. Clin Exp Immunol2013; 174: 292–301.
40.
PinedaMAAl-RiyamiLHarnettWHarnettM. Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis. Clin Exp Immunol2014; 177: 13–23.
41.
DoisneJMSoulardVBécourtC. Cutting edge: Crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1– invariant NKT cells to bacteria. J Immunol2011; 186: 662–666.
42.
HamiltonJA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol2008; 8: 533–544.
CookADPobjoyJSarrosS. Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain. Ann Rheum Dis2013; 72: 265–270.
45.
SondereggerIIezziGMaierRSchmitzNKurrerMKopfM. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med2008; 205: 2281–2294.
46.
ChangJBurkettPRBorgesCMKuchrooVKTurkaLAChangCH. MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc Natl Acad Sci U S A2013; 110: 2270–2275.
47.
O’SheaJJPlengeR. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity2012; 36: 542–550.
48.
HarnettWDeehanMRHoustonKMHarnettMM. Immunomodulatory properties of a phosphorylcholine-containing secreted filarial glycoprotein. Parasite Immunol1999; 21: 601–608.
49.
ChoyE. Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford)2012; 51(Suppl 5): v3–v11.
50.
KonistiSKiriakidisSPaleologEM. Hypoxia – a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol2012; 8: 153–162.
51.
ChangXWeiC. Glycolysis and rheumatoid arthritis. Int J Rheum Dis2011; 14: 217–222.
52.
ShaoSHeFYangYYuanGZhangMYuX. Th17 cells in type 1 diabetes. Cell Immunol2012; 280: 16–21.
53.
ChenLLeiLChangX. Mice deficient in MyD88 develop a Th2-dominant response and severe pathology in the upper genital tract following Chlamydia muridarum infection. J Immunol2010; 184: 2602–2610.
54.
RodgersDTPinedaMAMcGrathMAAl-RiyamiLHarnettWHarnettMM. Protection against collagen-induced arthritis in mice afforded by the parasitic worm product, ES-62, is associated with restoration of the levels of interleukin-10-producing B cells and reduced plasma cell infiltration of the joints. Immunology2014; 141: 457–466.
55.
HarnettMMMelendezAJHarnettW. The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease. Clin Exp Immunol2010; 159: 256–267.
56.
PinedaMARodgersDTAl-RiyamiLHarnettWHarnettM. ES-62 protects against collagen-induced arthritis by resetting IL-22 towards resolution of inflammation in the joints. Arthritis Rheumatol2014; 66: 1492–1503.
57.
LeeSYYoonBYKimJI. Interleukin-17 increases the expression of Toll-like receptor 3 via the STAT3 pathway in rheumatoid arthritis fibroblast-like synoviocytes. Immunology2014; 141: 353–361.
58.
MurakamiMHiranoT. The pathological and physiological roles of IL-6 amplifier activation. Int J Biol Sci2012; 8: 1267–1280.
59.
GeboesLDumoutierLKelchtermansH. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum2009; 60: 390–395.
60.
BesnardAGSabatRDumoutierL. Dual role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am J Respir Crit Care Med2011; 183: 1153–1163.
61.
LaurenceAO’SheaJJWatfordWT. Interleukin-22: A sheep in wolf’s clothing. Nat Med2008; 14: 247–249.
62.
ZenewiczLAYancopoulosGDValenzuelaDMMurphyAJStevensSFlavellRA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity2008; 29: 947–957.
63.
ZhengYDanilenkoDMValdezP. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature2007; 445: 648–651.
64.
SarkarSZhouXJustaSBommireddySR. IL-22 reduces the severity of collagen arthritis in association with increased levels of IL-10. Arthritis Rheum2013; 65: 960–971.
65.
HarnettWHarnettMM. Filarial nematode secreted product ES-62 is an anti-inflammatory agent: Therapeutic potential of small molecule derivatives and ES–62 peptide mimetics. Clin Exp Pharmacol Physiol2006; 33: 511–518.
66.
HarnettWHoustonKMTateR. Molecular cloning and demonstration of an aminopeptidase activity in a filarial nematode glycoprotein. Mol Biochem Parasitol1999; 104: 11–23.
67.
DeehanMRGoodridgeHSBlairD. Immunomodulatory properties of Ascaris suum glycosphingolipids – phosphorylcholine and non-phosphorylcholine-dependent effects. Parasite Immunol2002; 24: 463–469.
68.
HarnettWHarnettMM. Phosphorylcholine: Friend or foe of the immune system?Immunol Today1999; 20: 125–129.
69.
GoodridgeHSMarshallFAWilsonEH. In vivo exposure of murine dendritic cell and macrophage bone marrow progenitors to the phosphorylcholine-containing filarial nematode glycoprotein ES-62 polarizes their differentiation to an anti-inflammatory phenotype. Immunology2004; 113: 491–498.
70.
HarnettMMKeanDEBoitelleA. The phosphorycholine moiety of the filarial nematode immunomodulator ES-62 is responsible for its anti-inflammatory action in arthritis. Ann Rheum Dis2008; 67: 518–523.
71.
Al-RiyamiLPinedaMARzepeckaJ. Designing anti-inflammatory drugs from parasitic worms: A synthetic small molecule analogue of the Acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis. J Med Chem2013; 56: 9982–10002.
72.
GenoveseMCDurezPRichardsHB. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: A phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis2013; 72: 863–869.
73.
GenoveseMCVan den BoschFRobersonSA. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum2010; 62: 929–939.
74.
PappKALeonardiCMenterA. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med2012; 366: 1181–1189.
75.
HueberWSandsBELewitzkyS. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut2012; 61: 1693–1700.
76.
SpulsPIHooftL. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: A critical appraisal. Br J Dermatol2012; 167: 710–713. discussion 714–715).
77.
LeonardiCMathesonRZachariaeC. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med2012; 366: 1190–1199.
78.
SummersRWElliottDEUrbanJFJrThompsonRWeinstockJV. Trichuris suis therapy in Crohn’s disease. Gut2005; 54: 87–90.
79.
RoscheBWerneckeKDOhlraunSDorrJMPaulF. Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): Study protocol for a randomized controlled trial. Trials2013; 14: 112–112.
80.
SandbornWJElliottDEWeinstockJ. Randomised clinical trial: The safety and tolerability of Trichuris suis ova in patients with Crohn’s disease. Aliment Pharmacol Ther2013; 38: 255–263.
81.
BagerPKapelCRoepstorffA. Symptoms after ingestion of pig whipworm Trichuris suis eggs in a randomized placebo-controlled double-blind clinical trial. PLoS One2011; 6: e22346–e22346.
82.
de FaireUFrostegårdJ. Natural antibodies against phosphorylcholine in cardiovascular disease. Ann N Y Acad Sci2009; 1173: 292–300.
83.
KoulisCChenYCHausdingC. Protective role for Toll-like receptor-9 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol2014; 34: 516–525.
